RIGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RIGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Rigel Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.5 Mil. Rigel Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $59.8 Mil. Rigel Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $139.4 Mil. Rigel Pharmaceuticals's debt to asset for the quarter that ended in Sep. 2024 was 0.43.
The historical data trend for Rigel Pharmaceuticals's Debt-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Asset | Get a 7-Day Free Trial | 0.25 | 0.35 | 0.18 | 0.31 | 0.52 |
Rigel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Debt-to-Asset | Get a 7-Day Free Trial | 0.53 | 0.52 | 0.48 | 0.47 | 0.43 |
For the Biotechnology subindustry, Rigel Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Debt-to-Asset falls into.
Debt to Asset measures the financial leverage a company has.
Rigel Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-Asset | = | Total Debt | / | Total Assets | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Assets | |
= | (7.921 | + | 52.658) | / | 117.225 | |
= | 0.52 |
Rigel Pharmaceuticals's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as
Debt-to-Asset | = | Total Debt | / | Total Assets | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Assets | |
= | (0.466 | + | 59.762) | / | 139.419 | |
= | 0.43 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (NAS:RIGL) Debt-to-Asset Explanation
In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.
Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
David A Santos | officer: EVP, Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Dean L Schorno | officer: EVP & Chief Financial Officer | 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Raul R Rodriguez | officer: Sr VP of Bus Dev and Com Ops | 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Wolfgang Dummer | officer: EVP & CMO | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Raymond J. Furey | officer: EVP, GC & Corp Sec | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Alison L. Hannah | director | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Brian L. Kotzin | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060 |
Kamil Ali-jackson | director | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Jane Wasman | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Nelson Cabatuan | officer: Principal Accounting Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anne-marie Duliege | officer: Chief Medical Officer | 4001 MIRANDA AVENUE, PALO ALTO CA 94304 |
Mayer Eldon C. Iii | officer: EVP & Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Stacy Markel | officer: EVP Human Resources | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PRNewswire • 11-12-2024
By PRNewswire • 06-03-2024
By PRNewswire • 10-31-2024
By PRNewswire • 11-07-2024
By GuruFocus Research • 05-08-2024
By PRNewswire • 12-02-2024
By PRNewswire • 10-04-2024
By PRNewswire • 10-24-2024
By GuruFocus News • 11-07-2024
By GuruFocus Research • 08-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.